Cytek Biosciences (CTKB) Cash from Investing Activities (2020 - 2026)

Cytek Biosciences has reported Cash from Investing Activities for 7 years, with the latest figure at -$27.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 386.49% year-over-year to -$27.1 million; the trailing twelve-month figure through Mar 2026 stood at -$26.4 million (up 61.02% YoY), and the FY2025 full-year result was $10.1 million, up 112.19% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$27.1 million, down from -$1.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $43.1 million in Q3 2023, with the low at -$168.9 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged -$14.7 million across 5 years, with a median of -$1.8 million in 2025.
• The largest YoY upside for Cash from Investing Activities was 3849.91% in 2023 against a maximum downside of 21550.51% in 2023.
• Cytek Biosciences' Cash from Investing Activities stood at -$51.1 million in 2022, then jumped by 156.92% to $29.1 million in 2023, then tumbled by 318.24% to -$63.4 million in 2024, then surged by 97.1% to -$1.8 million in 2025, then slumped by 1370.09% to -$27.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$27.1 million (Q1 2026), -$1.8 million (Q4 2025), and $18.9 million (Q3 2025), per Business Quant data.